IBRX Q1 2025 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+41192.5% YoY

Gross Profit

$16M99.6% margin

Operating Income

-$64M-390.1% margin

Net Income

-$130M-784.9% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

+118.7%

Cash Flow

Operating Cash Flow

-$86M

Free Cash Flow

-$87M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$304M

Total Liabilities

$894M

Stockholders' Equity

-$591M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$40,000	+41192.5%
Gross Profit	$16M	$40,000	+41047.5%
Operating Income	-$64M	-$95M	+32.3%
Net Income	-$130M	-$134M	+3.3%

Revenue Segments

Product

$17M100%

Product and Service, Other

$8,0000%

Geographic Segments

UNITED STATES

$17M100%